MedTrace Logo

Effects of Ticagrelor Versus Prasugrel on Coronary Microcirculation in Patients Undergoing Elective Percutaneous Coronary Intervention: Results of the PROtecting MICROcirculation During Coronary Angioplasty (PROMICRO)-3 Randomised Study

NCT05643586 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2022-12-08

No results posted yet for this study

Summary

Besides being at least as effective as prasugrel in inhibiting platelet aggregation, ticagrelor has been shown to have additional properties potentially affecting coronary microcirculation. We sought to compare the effects of ticagrelor and prasugrel on absolute coronary blood flow (Q) and microvascular resistance (R) in patients with stable coronary artery disease (CAD) undergoing elective percutaneous coronary intervention (PCI).

The PROMICRO-3 study shows that in patients with stable CAD undergoing PCI pre-treatment with a loading dose of ticagrelor compared with prasugrel improves post-procedural coronary flow and microvascular function and seems to reduce the related myocardial injury.

Conditions

Interventions

DRUG

Ticagrelor

Patient treated with 180 mg ticagrelor 12 hours before the procedure

DRUG

Prasugrel

Patient treated with 60 mg prasugrel 12 hours before the procedure

Sponsors & Collaborators

  • Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium

    collaborator UNKNOWN

  • Department of Advanced Biomedical Sciences, University of Naples Federico II, Italy

    collaborator UNKNOWN

  • CardioRISC, C-TRIC, Derry/Londonderry, Northern Ireland, UK

    collaborator UNKNOWN

  • University of Lausanne Hospitals

    collaborator OTHER

  • Germano Di Sciascio

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-01
Primary Completion
2019-04-14
Completion
2019-04-14

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05643586 on ClinicalTrials.gov